Dr. Franson has served as the chief medical officer of YourEncore, an advisory firm focused on global life sciences and consumer health companies, since May 2014. From 2009 until May 2014, he was a principal of FaegreBD Consulting, a clinical and regulatory pharmaceutical development consulting firm, and currently maintains a relationship with FaegreBD through its strategic alliance with YourEncore. From 2008 until 2009, Dr. Franson served as the founder and president of Franson PharmaAdvisors LLC, a clinical and regulatory pharmaceutical development consulting firm. Prior to assuming these roles, Dr. Franson was vice president of Global Regulatory Affairs at Lilly Research Laboratories, a part of Eli Lilly and Company, which he joined in 1986. Dr. Franson is integrally involved in global public health initiatives through the US Pharmacopeial Convention (USP), currently serving as the president of this organization and on the executive committee of the USP Board of Trustees. He serves on the Board of Directors of Paratek Pharmaceuticals and the Critical Path Institute, which collaborates with FDA and industry in innovation advances. Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics, and antibiotic utilization. He holds a B.S. in pharmacy from Drake University and an M.D. from the University of Illinois College of Medicine. He is board certified in Internal Medicine and Infectious Diseases.

Dr. Franson has served as the chief medical officer of YourEncore, an advisory firm focused on global life sciences and consumer health companies, since May 2014. From 2009 until May 2014, he was a principal of FaegreBD Consulting, a clinical and regulatory pharmaceutical development consulting firm, and currently maintains a relationship with FaegreBD through its strategic alliance with YourEncore. From 2008 until 2009, Dr. Franson served as the founder and president of Franson PharmaAdvisors LLC, a clinical and regulatory pharmaceutical development consulting firm. Prior to assuming these roles, Dr. Franson was vice president of Global Regulatory Affairs at Lilly Research Laboratories, a part of Eli Lilly and Company, which he joined in 1986. Dr. Franson is integrally involved in global public health initiatives through the US Pharmacopeial Convention (USP), currently serving as the president of this organization and on the executive committee of the USP Board of Trustees. He serves on the Board of Directors of Paratek Pharmaceuticals and the Critical Path Institute, which collaborates with FDA and industry in innovation advances. Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics, and antibiotic utilization. He holds a B.S. in pharmacy from Drake University and an M.D. from the University of Illinois College of Medicine. He is board certified in Internal Medicine and Infectious Diseases.